AEG35156, an investigative drug may help increase the survival time of patients suffering from late stage liver cancer.
The drug code-named AEG35156, developed by Aegera Therapeutics Inc, has been found delaying the survival rate of patients when given in combination with other treatment against liver cancer.
This study, entitled “A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma”, is being conducted exclusively in Hong Kong.
The data from 13 patients treated with drug indicated that AEG35156 is also safe in patients.
“I am greatly encouraged by this interim data read and look forward to completing this study as quickly as possible to ascertain whether the improved survival data can be confirmed in the Phase 2 portion of the trial, ” stated Dr. Jacques Jolivet, senior vice-President, Clinical of the trial’s sponsor, Aegera Therapeutics.
AEG35156 is a 2nd generation antisense oligonucleotide. This targeted therapy is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells.
“We are excited about the results of the Phase I portion and now focused on completing recruitment to the randomized Phase 2 portion of the clinical trial to confirm the therapeutic benefit of the AEG35156/sorafenib combination” stated Professor Benny Chung-Ying Zee, PhD, Director of the Centre for Clinical Trials, School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong.
Aegera is also working on several preclinical programs in the area of autoimmune, inflammatory and central nervous system diseases.
Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies. In addition to AEG35156, Aegera is working with its partner Human Genome Sciences to progress HGS1029 through early stage clinical development for oncology and is also actively working on several preclinical programs in the area of
autoimmune, inflammatory and central nervous system diseases.